(Albany, United States) As per DelveInsight’s assessment, globally, the Metastatic Pancreatic Cancer pipeline constitutes 25+ key companies continuously working towards developing 25+ Metastatic Pancreatic Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Metastatic Pancreatic Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic Pancreatic Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Metastatic Pancreatic Cancer pipeline treatment landscape of the report, click here @ Metastatic Pancreatic Cancer Pipeline Outlook

 

Key Takeaways from the Metastatic Pancreatic Cancer Pipeline Report

• DelveInsight’s Metastatic Pancreatic Cancer Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline treatment therapies.
• The leading Metastatic Pancreatic Cancer Companies in the market include Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others
• Promising Metastatic Pancreatic Cancer Pipeline Therapies in the various stages of development include ACP-196, Galunisertib, Durvalumab, Salmonella-IL2, FOLFIRINOX Alone (Historical Controls), Gemcitabine, Albumin-bound paclitaxel, Azeliragon, IOA-289, RX-3117, Olaratumab, Nanoplatin (NC-6004), SGT-53, MM-398, Leucovorin, and others.
• On June 2023, Cantex Pharmaceuticals announced a study of phase 1 clinical trials for Azeliragon. This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patient’s refractory to first-line or second-line treatment of metastatic pancreatic cancer.
• On May 2023, M.D. Anderson Cancer Center announced a study of phase 1 clinical trials for MRTX849. To learn if the investigational study drug, adagrasib (also called MRTX849), can help to control pancreatic cancer that has a KRAS G12 mutation. The safety and possible effects of adagrasib will also be studied.

 

Metastatic Pancreatic Cancer Overview

Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. The 5-year survival rate in the United States ranges from 5% to 15%.

 

To explore more information on the latest breakthroughs in the Metastatic Pancreatic Cancer Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight

 

Metastatic Pancreatic Cancer Emerging Drugs Profile

• Motixafortide: BioLineRx
• Fuzuloparib: Jiangsu Hengrui Pharmaceuticals
• HP518: Hinova Pharmaceuticals

 

Metastatic Pancreatic Cancer Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies Metastatic Pancreatic Cancer. The Metastatic Pancreatic Cancer companies which have their Metastatic Pancreatic Cancer drug candidates in the most advanced stage, i.e phase III include Eleison Pharmaceuticals.

 

Request a sample and discover the recent advances in Metastatic Pancreatic Cancer Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight

 

Metastatic Pancreatic Cancer Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Metastatic Pancreatic Cancer Therapeutics Market include-

Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others.

 

Dive deep into rich insights for drugs for Metastatic Pancreatic Cancer Pipeline, click here for Metastatic Pancreatic Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight

 

Scope of the Metastatic Pancreatic Cancer Pipeline Report

• Coverage- Global
• Metastatic Pancreatic Cancer Companies- Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others.
• Metastatic Pancreatic Cancer Pipeline Therapies- ACP-196, Galunisertib, Durvalumab, Salmonella-IL2, FOLFIRINOX Alone (Historical Controls), Gemcitabine, Albumin-bound paclitaxel, Azeliragon, IOA-289, RX-3117, Olaratumab, Nanoplatin (NC-6004), SGT-53, MM-398, Leucovorin, and others.
• Metastatic Pancreatic Cancer Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Metastatic Pancreatic Cancer Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/metastatic-pancreatic-cancer-mpc-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Pancreatic Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Pancreatic Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Rucaparib: Eleison Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MDB 401 B: Panbela Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SBP 101: Takeda Oncology
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Pancreatic Cancer Key Companies
21. Metastatic Pancreatic Cancer Key Products
22. Metastatic Pancreatic Cancer- Unmet Needs
23. Metastatic Pancreatic Cancer- Market Drivers and Barriers
24. Metastatic Pancreatic Cancer- Future Perspectives and Conclusion
25. Metastatic Pancreatic Cancer Analyst Views
26. Metastatic Pancreatic Cancer Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services